Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
GILEAD SCIENCES, INC.: Amended and restated bylaws to revise procedural and disclosure requirements for director nominations and stockholder proposals, reserve white proxy card, update provisions regarding adjournment and stockholder list under DGCL, clarify majority vote provisions, and add emergency condition provisions (effective 2025-07-30).
- Change
- bylaw amendment
- Effective
- 2025-07-30
Exact text from the filing
On July 30, 2025 , the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”), effective as of such date, in order to: • revise the procedural and disclosure requirements for the nomination of directors and the submission of proposals for consideration at meetings of the stockholders under the advance notice provisions (other than proposals to be included in the Company’s proxy statement pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), including, without limitation, by: ◦ clarifying and enhancing the background information and disclosures required by or regarding proposing stockholders, proposed nominees and business, and other control persons or persons known to be acting in concert with a proposing stockholder, including with respect to certain plans or proposals of and any planned solicitation by such persons; ◦ clari
View on SEC.gov